Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE ...

The first week was the worst. “It was very, very, very deadly because the people had an advanced stage of disease, and the ...

BOTHELL, Wash., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three and nine months ended September 30, 2024, ...

At Delhi's RML Hospital, home to India's 1st pollution OPD, doctors estimate that number of patients coming in weekly has ...

With a test currently under FDA review, Inflammatix commences a 600 patient-strong clinical trial in emergency departments.

There is reason to be optimistic about the future of dengue antivirals, and funding of dengue research in general. The 2010 G-FINDER report revealed over US$165 million in total global funding to ...

Paxlovid significantly shortened the time to symptom relief (median, 13 vs 15 days; hazard ratio [HR], 1.27) and resolution ...

There is no real treatment for dengue, but vaccines have delivered some success. Yacoub is investigating different antivirals ...

Left untreated, chronic HCV can progress to cirrhosis, liver cancer, and even death. While no vaccine exists, direct-acting ...

Virus monitoring, the budgets to investigate E. coli outbreaks, and much, much more could be on the chopping block.

Bird flu (H5N1) has been spreading across the country, among both animals and people, since April of this year. As the ...

Therefore, it is quite difficult for a direct-acting antivirals to demonstrate the significant impact on the course of the disease. I am proud of our team's rigorous execution of this trial and we ...